# CONTACT-01 (NCT04471428)

> Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04471428
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Cabozantinib; Atezolizumab; Docetaxel
- Enrollment: 366
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 15
- Podcasts: 7

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=contact-01-nct04471428

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04471428", "email": "<work email>"}; the inbox owner confirms by the emailed link.